ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $13.60 million. The enterprise value is $20.12 million.
Important Dates
The next confirmed earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 41.54 million shares outstanding. The number of shares has increased by 41.23% in one year.
| Current Share Class | 41.54M |
| Shares Outstanding | 41.54M |
| Shares Change (YoY) | +41.23% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 12.59% |
| Float | 38.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.50 |
| Forward PS | 0.66 |
| PB Ratio | 0.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.65.
| Current Ratio | 0.96 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.06 |
Financial Efficiency
Return on equity (ROE) is -169.33% and return on invested capital (ROIC) is -42.77%.
| Return on Equity (ROE) | -169.33% |
| Return on Assets (ROA) | -28.30% |
| Return on Invested Capital (ROIC) | -42.77% |
| Return on Capital Employed (ROCE) | -187.19% |
| Revenue Per Employee | $48,104 |
| Profits Per Employee | -$431,792 |
| Employee Count | 96 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, ProPhase Labs has paid $12.83 million in taxes.
| Income Tax | 12.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.65% in the last 52 weeks. The beta is -0.47, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.47 |
| 52-Week Price Change | -87.65% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.55 |
| Relative Strength Index (RSI) | 45.31 |
| Average Volume (20 Days) | 15,293,881 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $4.62 million and -$41.45 million in losses. Loss per share was -$1.36.
| Revenue | 4.62M |
| Gross Profit | 1.65M |
| Operating Income | -30.73M |
| Pretax Income | -32.20M |
| Net Income | -41.45M |
| EBITDA | -24.80M |
| EBIT | -30.73M |
| Loss Per Share | -$1.36 |
Full Income StatementBalance Sheet
The company has $169,000 in cash and $7.48 million in debt, giving a net cash position of -$7.31 million or -$0.18 per share.
| Cash & Cash Equivalents | 169,000 |
| Total Debt | 7.48M |
| Net Cash | -7.31M |
| Net Cash Per Share | -$0.18 |
| Equity (Book Value) | 11.44M |
| Book Value Per Share | 0.28 |
| Working Capital | -1.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.18 million and capital expenditures -$39,000, giving a free cash flow of -$15.82 million.
| Operating Cash Flow | -11.18M |
| Capital Expenditures | -39,000 |
| Free Cash Flow | -15.82M |
| FCF Per Share | -$0.38 |
Full Cash Flow StatementMargins
| Gross Margin | 35.64% |
| Operating Margin | -665.40% |
| Pretax Margin | -739.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |